Regeneron Pharmaceuticals, Inc. has made progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected. Regeneron has now isolated hundreds of virus-neutralizing, fully human antibodies from the company’s VelocImmune mice, which have been genetically-modified to have a human immune system. Regeneron has also isolated antibodies from humans who have...